Table 3.
Crossover analysis of the PTC-related interactions between SNPs of RAS genes
| Loci combinations | PTC | Control | OR (95%CI) | S | RERI | AP | P | |
|---|---|---|---|---|---|---|---|---|
| rs12427141* rs12628 |
||||||||
| + | + | 61 | 62 | 1.098 (0.742-1.627) | 0.121 | -0.709 | -0.646 | <0.05 |
| + | - | 131 | 87 | 1.681 (1.220-2.316) | ||||
| - | + | 232 | 230 | 1.126 (0.877-1.446) | ||||
| - | - | 249 | 278 | 1 | ||||
| rs12427141*rs14804 | ||||||||
| + | + | 12 | 5 | 2.531 (0.885-7.240) | 17.398 | 1.443 | 0.507 | >0.05 |
| + | - | 193 | 182 | 1.118 (0.880-1.421) | ||||
| - | + | 23 | 25 | 0.970 (0.543-1.734) | ||||
| - | - | 458 | 483 | 1 | ||||
| rs12427141*rs2273267 | ||||||||
| + | + | 83 | 72 | 1.240 (0.866-1.776) | 0.430 | -0.318 | -0.256 | >0.05 |
| + | - | 103 | 73 | 1.518 (1.074-2.144) | ||||
| - | + | 230 | 238 | 1.040 (0.810-1.334) | ||||
| - | - | 251 | 270 | 1 | ||||
| rs12628*rs14804 | ||||||||
| + | + | 14 | 11 | 1.227 (0.549-2.739) | 10.318 | 0.205 | 0.167 | >0.05 |
| + | - | 279 | 281 | 0.957 (0.766-1.195) | ||||
| - | + | 21 | 19 | 1.065 (0.563-2.016) | ||||
| - | - | 359 | 346 | 1 | ||||
| rs12628*rs2273267 | ||||||||
| + | + | 101 | 99 | 0.969 (0.689-1.363) | 0.564 | 0.024 | 0.025 | >0.05 |
| + | - | 161 | 158 | 0.968 (0.720-1.302) | ||||
| - | + | 181 | 176 | 0.977 (0.733-1.302) | ||||
| - | - | 199 | 189 | 1 | ||||
| rs12628*rs712 | ||||||||
| + | + | 14 | 11 | 1.626 (0.723-3.657) | 0.448 | -0.770 | -0.474 | >0.05 |
| + | - | 192 | 193 | 1.271 (0.968-1.667) | ||||
| - | + | 178 | 107 | 2.125 (1.570-2.875) | ||||
| - | - | 202 | 258 | 1 | ||||
| rs12628*rs7315339 | ||||||||
| + | + | 67 | 82 | 0.798 (0.557-1.144) | -1.365 | -0.35 | -0.439 | >0.05 |
| + | - | 226 | 210 | 1.052 (0.822-1.345) | ||||
| - | + | 74 | 66 | 1.096 (0.758-1.583) | ||||
| - | - | 306 | 299 | 1 | ||||
| rs14804*rs712 | ||||||||
| + | + | 14 | 10 | 1.618 (0.710-3.685) | 0.797 | -0.157 | -0.097 | >0.05 |
| + | - | 21 | 20 | 1.213 (0.648-2.273) | ||||
| - | + | 265 | 196 | 1.562 (1.240-1.968) | ||||
| - | - | 373 | 431 | 1 | ||||
| rs14804*rs7315339 | ||||||||
| + | + | 4 | 6 | 0.645 (0.181-2.301) | -1.929 | -0.539 | -0.836 | >0.05 |
| + | - | 31 | 24 | 1.250 (0.723-2.162) | ||||
| - | + | 137 | 142 | 0.934 (0.716-1.218) | ||||
| - | - | 501 | 485 | 1 | ||||
| rs2273267*rs712 | ||||||||
| + | + | 120 | 83 | 1.611 (1.149-2.260) | 1.571 | 0.222 | 0.138 | >0.05 |
| + | - | 193 | 227 | 0.948 (0.723-1.242) | ||||
| - | + | 159 | 123 | 1.441 (1.064-1.950) | ||||
| - | - | 201 | 224 | 1 | ||||
| rs2273267*rs7315339 | ||||||||
| + | + | 72 | 76 | 0.895 (0.623-1.286) | -0.195 | -0.643 | 0.718 | <0.05 |
| + | - | 171 | 99 | 1.632 (1.212-2.198) | ||||
| - | + | 69 | 72 | 0.906 (0.626-1.310) | ||||
| - | - | 291 | 275 | 1 | ||||
Notes: +, Mutant heterozygote and homozygous; -, Unmutated wild type.
Abbreviations: PTC, papillary thyroid carcinoma; S, synergy index; RERI, relative excess risk due to interaction; AP: attributable proportion due to interaction.